BRAF and neoplasm: Moreover, the authors found BRAF V600E tumors show both lower CD8(+) effector to FoxP3(+) regulatory T cell, and CD68(+) pan-macrophage to CD163(+) M2 macrophage, ratios, and suggested that PTC tumors with BRAF V600E displays a broadly immunosuppressive profile and disturbed host tumor immune surveillance [72].